




Data in Support of Novavax XBB.1.5 Vaccine

Dr. Filip Dubovsky, President, Research & Development
September 12, 2023

Novavax Vaccine Platform: Recombinant Protein Particle Plus Matrix-M™ Adjuvant



Recombinant protein particle

- Native 3-dimensional conformation
- Truncated *S. frugiperda* glycans
- Particulate structure facilitates antigen presentation and processing



Matrix-M adjuvant

- Induces robust neutralizing antibodies
- Induces polyfunctional CD4+ Th1



**Novavax
2023-2024 vaccine**

Novavax XBB.1.5 Vaccine 2023-2024 Formulation for Individuals ≥ 12 years



Presentation

- 2 vials per carton
- 5 doses per vial
- 0.5 mL dose
- Ready to use



Transportation & Storage

- Stable at 2°C to 8°C
- 9-month shelf life*
- Use within 12 hours of first puncture



Dosing*

- Single dose for previously vaccinated with any COVID-19 vaccine
- If unvaccinated, 2-dose series




XBB.1.5 Primary Series Neutralizing Responses

Non-human primate data demonstrates Novavax vaccine technology induces broadly neutralizing antibodies with primary vaccination

Neutralizing Responses in Macaques: Primary Vaccination with XBB.1.5

Primary vaccination induces comparable neutralizing responses to newly emerging variants






XBB.1.5 Booster Dose Neutralizing Responses

*Neutralizing responses against XBB subvariants
achieve levels comparable to homologous XBB.1.5
response*

Neutralizing Responses in Macaques: Primary Vaccination Bivalent BA.5 Vaccine and Boost with XBB.1.5

Boosting with XBB.1.5 induces robust neutralizing responses against emerging XBB subvariants

Bivalent Primary and XBB.1.5 Booster Dose






Cellular Immune Responses

Consistent responses against all variants including emerging XBB subvariants

Th1-Biased CD4+ T Cell Response in Rhesus Macaques Immunized with Two Doses of XBB.1.5 Vaccine

Consistent responses against all variants including emerging XBB subvariants



Public Health Value of Novavax XBB.1.5 Vaccine

- Only protein-based COVID-19 vaccine in US
- Non-clinical data supports use of Novavax XBB.1.5 vaccine
 - Induces robust neutralizing responses against XBB subvariants
 - Generates a polyfunctional Th1-biased CD4+ cellular immune response against XBB subvariants
- Presentation facilitates ease of use
 - Same dose/formulation/vial for all approved indications (0.5mL/dose)
 - Ready to use and refrigerator stable (no mixing, dilution or thawing)